ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2825

Characterization of Mesenchymal Stem Cells Generated from Axial Spondyloarthritis Patient-Derived Induced Pluripotent Stem Cells

Gerlinde Layh-Schmitt1, Shajia Lu1, Emily Lazowick1, Stephen Brooks1, Massimo Gadina1 and Robert A. Colbert2, 1NIAMS/NIH, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: IPS (induced pluripotent stem cells), mesenchymal stem cells and spondylarthropathy

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Ankylosing spondylitis (AS) is an immune-mediated inflammatory disease associated with trabecular bone loss and concomitant aberrant bone formation in the spine. Over 40 genes or genetic regions have been associated with the risk of developing AS. The impact of these genes on disease pathogenesis and the cell types that mediate these effects remain largely unknown. To begin to address these questions we generated induced pluripotent stem cells (iPSCs) from fibroblasts of axial spondyloarthritis (AxSpA) patients and healthy controls (HC), differentiated them into disease-relevant cell lineages like mesenchymal stem cells (MSCs) and osteoblasts (OBs), and analyzed comprehensive gene expression patterns and expression levels of AS risk genes in iPSCs and MSCs using whole blood as a comparison.

Methods: Dermal fibroblasts from two AxSpA patients and one HC were reprogrammed using a Sendai virus vector encoding OCT4, SOX2, KLF4 and MYC. Virus-free iPSCs were differentiated into MSCs using a TGF-β inhibitor. MSCs were differentiated into osteoblasts, by culturing them in cell type specific differentiation media. Immunofluorescence microscopy and flow cytometry were conducted to evaluate the expression of lineage specific markers. Genome-wide gene expression patterns in iPSCs and MSCs were compared with whole blood using RNA-Seq followed by Principle Components Analysis (PCA) and Ingenuity Pathway Analysis (IPA).

Results: Reprogrammed lines expressed iPSC-specific genes and proteins, and iPSCs were successfully differentiated into functional MSCs. Gene expression analysis revealed distinct cell type-specific clusters and differentially expressed pathways identified by IPA. The expression of known AS risk genes in iPSCs and MSCs was compared to peripheral blood, revealing several genes that were highly enriched in MSCs (e.g. EDIL3, ANO6, HAPLN1) or expressed at high levels, but comparable to blood (TNFRSF1, TYK2, SH2B3, and STAT3). MSCs were further differentiated into osteoblasts. Differences in osteoblast mineralization potential between subject-derived lines were consistent in duplicate iPSC derivations, with the AxSpA patient exhibiting 3-fold higher mineralization than the HC along with increased expression of alkaline phosphatase (ALP) mRNA in patient lines, whereas other genes associated with osteoblast differentiation (etc. RUNX2, Osterix) were expressed equally in all lines.

Conclusion: AxSpA patient-derived iPSCs demonstrated pluripotency, lineage-specific gene expression patterns, and could be differentiated into disease-relevant cell types. A subset of risk genes was expressed predominantly in MSCs, underscoring the potential utility of these cells in studying pathogenic mechanisms. Moreover, enhanced OB mineralization potential was reproducible in separate iPSC derivations from the same individuals. We are currently generating more lines to determine whether this is a disease characteristic. In summary, skin fibroblast-derived iPSCs provide a powerful system to explore the functional genomics of AS risk genes that may impact bone formation.


Disclosure: G. Layh-Schmitt, None; S. Lu, None; E. Lazowick, None; S. Brooks, None; M. Gadina, None; R. A. Colbert, None.

To cite this abstract in AMA style:

Layh-Schmitt G, Lu S, Lazowick E, Brooks S, Gadina M, Colbert RA. Characterization of Mesenchymal Stem Cells Generated from Axial Spondyloarthritis Patient-Derived Induced Pluripotent Stem Cells [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/characterization-of-mesenchymal-stem-cells-generated-from-axial-spondyloarthritis-patient-derived-induced-pluripotent-stem-cells/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-mesenchymal-stem-cells-generated-from-axial-spondyloarthritis-patient-derived-induced-pluripotent-stem-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology